← boardnext 2027-08
CLYM
Climb Bio, Inc.distress 3/10 · well-funded / low risk$12.46-1%today-11% from 52w high
Lead: IgA nephropathy
Revenue
pre-revenue
Liquidity
$146M
Runway
2.7 yrs
Shares 1y
-15%
Price & events
+153.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
-1.0%
1W
+1.3%
1M
+38.1%
3M
+148.2%
6M
+741.9%
1Y
+39.5%
2Y
—
5Y
-21.6%
All
Overview
- Market Cap
- $713.47M
- Volume
- 47.71K
- 52 Week Range
- $1.37 – $14.00
- Total Shares
- 57.26M
- Float Shares
- 41.43M
- Short %
- 12.57%
- % Held by Insiders
- 0.37%
- % Held by Institutions
- 64.56%
- RVOL
- 0.03x
- Beta
- 0.07
Pipeline stages · 2 programs
budoprutug
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CLYM116
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 1/2 | Budoprutugfast trackorphan | Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19 | — | recruiting |
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 1/2 | Budoprutugfast trackorphan | Systemic Lupus Erthematosus | — | not yet recruiting |
| 2027-10 Estimated 50% readout ~2027-11-15 | Phase 2 | budoprutugfast trackorphan | Primary Membranous Nephropathy | — | recruiting |
| 2026-07 | Phase 1 | CLYM116 | Healthy Volunteers | 48 | recruiting |
Catalyst news & presentations · 12
- year-end 2026Guided 70%readoutPhase 1/2budoprutug · Additional data from Phase 1b/2a studySEC 8-K
- third quarter of 2026Guided 70%trial initiationsecondaryPhase 2CLYM116 · Initiate dosing in IgAN patients in Phase 2 portion of ongoing studySEC 8-K
- mid-year 2026readoutPhase 1CLYM116 · Initial biomarker and dosing interval dataSEC 8-K
- June 2026readoutPhase 1/2budoprutug · Initial B-cell and platelet data from low dose cohort (250 mg at 24 weeks)SEC 8-K
- first half of 2026trial initiationsecondaryPhase 1budoprutug · First patient dose in China SLE trialSEC 8-K
- 2025trial initiationsecondaryPhase 3budoprutug · Advancement to late phase developmentSEC 8-K
- Q4 2025trial initiationsecondaryPhase 1CLYM116 · Initiate Phase 1 trial in healthy volunteersSEC 8-K
- September 29, 2025conferencedata presentationsecondaryCLYM116 · Virtual investor event presenting preclinical NHP dataSEC 8-K
- first half of 2025conferencedata presentationsecondarybudoprutug · Non-clinical data expected for subcutaneous formulationSEC 8-K
- first half of 2025trial initiationsecondaryPhase 2budoprutug · Initiation of Phase 2 single-arm open-label study in chronic ITPSEC 8-K
- 2025-01-08partnershipCLYM116 · Exclusive license from Mabworks for MIL116 outside China; $9M upfront, up to $832M milestones plus royaltiesSEC 8-K
- October 24, 2024conferencedata presentationsecondaryPhase 1budoprutug · Poster presentation at ASN Kidney Week 2024 of additional Phase 1b dataSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $21 (+68% upside) · 14 analysts
- 2026-06-24HC Wainwright & Co.Buy
- 2026-06-12WedbushOutperform
- 2026-06-11BTIGBuy
- 2026-06-08GuggenheimBuy
- 2026-06-08BTIGBuy
- 2026-05-12HC Wainwright & Co.Buy
Competitors — IgA nephropathy
Recent news
- 2026-07-15FMR LLC's Strategic Acquisition of Climb Bio Inc Shares - GuruFocus
- 2026-07-15FMR LLC's Strategic Acquisition of Climb Bio Inc Shares - GuruFocus
- 2026-07-09Climb Bio Inc. (CLYM) Edges Lower Amid Mixed Biotech Sentiment, Key Support Levels in Focus - Weak Sell Signals - DonanımHaber
- 2026-07-09Climb Bio Inc. (CLYM) Q1 2026 Earnings: Smaller-Than-Expected Loss Signals Cost Discipline - Negative Surprise Momentum - dars.gov.et
- 2026-07-08CLYM Q1 2026 Earnings: Narrower Loss than Expected, Stock Edges Higher - Geographic Revenue Trends - dars.gov.et
- 2026-07-07Form 13D/A Climb Bio For: 7 July By Investing.com - Investing.com Canada
- 2026-07-06Climb Bio Inc. (CLYM) Q1 2026 Earnings: EPS Beat Partially Offsets Market Skepticism as Pre-Revenue Biotech Navigates Clinical Progress - Dividend Earnings Report - dars.gov.et
- 2026-07-02Climb Bio Appoints Breanna O’Reilly to Board - The Globe and Mail
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.